ArticleBMC cancer2024

Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.

Wataru Fukumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.